© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Innate Pharma S.A. (IPHA) shows an Average True Range (ATR) of 0.1 and an Enterprise Value of 154.98M. Its average trading volume over the past 3 months is 190.44K, indicating liquidity. These fundamental metrics provide insight into IPHA's underlying financial health and market activity.
Innate Pharma S.A. (IPHA) technical indicators as of January 1, 2026: the SMA 20 is -3.58%, SMA 50 at -7.82%, and SMA 200 at -11.95%. The RSI 14 value is 43.09, suggesting its current momentum. These technical analysis signals help assess IPHA's price trends and potential future movements.
Innate Pharma S.A. (IPHA) stock performance overview as of January 1, 2026: The 52-week high is $2.63 (currently -33.46% below), and the 52-week low is $1.6 (currently 9.37% above). Over the past year, IPHA's performance is -15.05%, compared to the S&P 500's 12.29% change.
According to market data, Innate Pharma S.A. (IPHA) stock's recent performance metrics show that over the last month, IPHA is -10.26%, with a Year-to-Date (YTD) performance of -4.89%. Over the past year, the stock has seen a -15.05% change. These figures summarize IPHA's price movements across various periods, reflecting its historical returns.
According to current financial data, IPHA stock's P/E (TTM) ratio is -2.71, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for IPHA, including P/S (24.01), P/B (24.30), and P/FCF (-2.99), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.